News & Updates
Filter by Specialty:

Tremelimumab plus durvalumab improves survival in Asians with unresectable HCC
28 Jan 2025
byStephen Padilla
A single tremelimumab regular interval durvalumab (STRIDE) provides survival benefits to Asian patients with unresectable hepatocellular carcinoma (HCC), as shown by the results of the HIMALAYA study.
Tremelimumab plus durvalumab improves survival in Asians with unresectable HCC
28 Jan 2025
Study finds DNA methylation profile for early breast cancer detection
28 Jan 2025
byAudrey Abella
Researchers from Singapore have found a whole blood-based DNA methylation biomarker profile that effectively distinguishes breast cancer patients from healthy controls.